ArticleAnalytical chemistry2013
Directly coupled high-performance liquid chromatography-accelerator mass spectrometry measurement of chemically modified protein and peptides.
Article in Analytical chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Human in Vivo Pharmacokinetics of [(14)C]Dibenzo[def,p]chrysene by Accelerator Mass Spectrometry Following Oral Microdosing.Chemical research in toxicology · 2015Trial
- Identification and Quantitation ofMethods and protocols · 2025Article
- Review
- Understanding the pharmacokinetic journey of Fc-fusion protein, rhIL-7-hyFc using complementary approach of two analytical methods, accelerator mass spectrometry and ELISA.Antibody therapeutics · 2024Article
- HPLC-Parallel accelerator and molecular mass spectrometry analysis ofJournal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2023Article
- Optimization of the LLNL/CAMS gas-accepting ion source and 1 MV compact AMS for natural abundance radiocarbon analysis of CONuclear instruments & methods in physics research. Section B, Beam interactions with materials and atoms · 2022Article
- Parallel Accelerator and Molecular Mass Spectrometry Measurement of Carbon-14-Labeled Analytes.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Conversion of the LLNL/CAMS 1 MV biological AMS system to a semi-automated natural abundanceNuclear instruments & methods in physics research. Section B, Beam interactions with materials and atoms · 2021Article
- Radiocarbon Tracers in Toxicology and Medicine: Recent Advances in Technology and Science.Toxics · 2019Review
- Naphthalene DNA Adduct Formation and Tolerance in the Lung.Nuclear instruments & methods in physics research. Section B, Beam interactions with materials and atoms · 2019Article
- Use of Accelerator Mass Spectrometry in Human Health and Molecular Toxicology.Chemical research in toxicology · 2016Review
- Human Microdosing with Carcinogenic Polycyclic Aromatic Hydrocarbons: In Vivo Pharmacokinetics of Dibenzo[def,p]chrysene and Metabolites by UPLC Accelerator Mass Spectrometry.Chemical research in toxicology · 2016Article
- Opportunities in low-level radiocarbon microtracing: applications and new technology.Future science OA · 2016Review
- An Interface for the Direct Coupling of Small Liquid Samples to AMS.Nuclear instruments & methods in physics research. Section B, Beam interactions with materials and atoms · 2015Article
- Operation of the "Small" BioAMS Spectrometers at CAMS: Past and Future Prospects.Nuclear instruments & methods in physics research. Section B, Beam interactions with materials and atoms · 2015Article
- Mass Spectrometric Characterization of Human Serum Albumin Adducts Formed with N-Oxidized Metabolites of 2-Amino-1-methylphenylimidazo[4,5-b]pyridine in Human Plasma and Hepatocytes.Chemical research in toxicology · 2015Article
- Use of microdosing and accelerator mass spectrometry to evaluate the pharmacokinetic linearity of a novel tricyclic GyrB/ParE inhibitor in rats.Antimicrobial agents and chemotherapy · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Quantitation of low-abundance protein modifications involves significant analytical challenges, especially in biologically important applications, such as studying the role of post-translational modifications in biology and measurement of the effects of reactive drug metabolites. (14)C labeling combined with accelerator mass spectrometry (AMS) provides exquisite sensitivity for such experiments. Here, we demonstrate real-time (14)C quantitation of high-performance liquid chromatography (HPLC) separations by liquid sample accelerator mass spectrometry (LS-AMS). By enabling direct HPLC-AMS coupling, LS-AMS overcomes several major limitations of conventional HPLC-AMS, where individual HPLC fractions must be collected and converted to graphite before measurement. To demonstrate LS-AMS and compare the new technology to traditional solid sample AMS (SS-AMS), reduced and native bovine serum albumin (BSA) was modified by (14)C-iodoacetamide, with and without glutathione present, producing adducts on the order of 1 modification in every 10(6) to 10(8) proteins. (14)C incorporated into modified BSA was measured by solid carbon AMS and LS-AMS. BSA peptides were generated by tryptic digestion. Analysis of HPLC-separated peptides was performed in parallel by LS-AMS, fraction collection combined with SS-AMS, and (for peptide identification) electrospray ionization and tandem mass spectrometry (ESI-MS/MS). LS-AMS enabled (14)C quantitation from ng sample sizes and was 100 times more sensitive to (14)C incorporated in HPLC-separated peptides than SS-AMS, resulting in a lower limit of quantitation of 50 zmol (14)C/peak. Additionally, LS-AMS turnaround times were minutes instead of days, and HPLC trace analyses required 1/6th the AMS instrument time required for analysis of graphite fractions by SS-AMS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.